Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation-Reference-Cited by-同舟云学术

Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation

Published:2022-12-09 Issue:4 Volume:89 Page:1471-1485
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Zwart Tom C.¹^ORCID,Bezstarosti Suzanne²,Achini Federica R.³,Reinders Marlies E. J.⁴,Schilham Marco W.³,Heidt Sebastiaan²,Guchelaar Henk‐Jan¹,de Fijter Johan W.⁴,Moes Dirk Jan A. R.¹

Affiliation:

1. Department of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The Netherlands

2. Department of Immunology Leiden University Medical Center Leiden The Netherlands

3. Department of Paediatrics Leiden University Medical Center Leiden The Netherlands

4. Department of Internal Medicine (Nephrology) and LUMC Transplant Center Leiden University Medical Center Leiden The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15608

Reference47 articles.

1. RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)

2. T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients

3. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients

4. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation;British Journal of Clinical Pharmacology;2024-07-26

2. Immunosuppressants against acute kidney injury: what to prefer or to avoid?;Immunopharmacology and Immunotoxicology;2024-03-18

3. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

4. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection;Transplant International;2023-11-07